

60. **Seagroves, T. N., J. P. Lydon, R. C. Hovey, B. K. Vonderhaar, and J. M. Rosen.** 2000. C/EBP β (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. *Mol. Endocrinol.* **14**:359–368.
61. **Shen, T., K. B. Horwitz, and C. A. Lange.** 2001. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. *Mol. Cell. Biol.* **21**:6122–6131.
62. **Skildum, A., E. Faivre, and C. A. Lange.** 2005. Progesterone receptors induce cell cycle progression via activation of mitogen activated protein kinases. *Mol. Endocrinol.* **19**:327–339.
63. **Takimoto, G. S., D. M. Tasset, A. C. Eppert, and K. B. Horwitz.** 1992. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. *Proc. Natl. Acad. Sci. USA* **89**:3050–3054.
64. **Tung, L., M. K. Mohamed, J. P. Hoeffler, G. S. Takimoto, and K. B. Horwitz.** 1993. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. *Mol. Endocrinol.* **7**:1256–1265.
65. **Wang, X., Y. Xiao, Y. Mou, Y. Zhao, W. M. Blankestijn, and J. L. Hall.** 2002. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. *Circ. Res.* **90**:340–347.
66. **Warren, M. P.** 2004. A comparative review of the risks and benefits of hormone replacement therapy regimens. *Am. J. Obstet. Gynecol.* **190**:1141–1167.
67. **Xu, K., Y. Ding, J. Ling, Z. Dong, and F. X. Yu.** 2004. Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. *Investig. Ophthalmol. Vis. Sci.* **45**:813–820.